| A SARS-CoV-2 protein interaction map reveals targets for drug repurposing DE Gordon, GM Jang, M Bouhaddou, J Xu, K Obernier, KM White, ... Nature 583 (7816), 459-468, 2020 | 4356 | 2020 |
| Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma D Miao, CA Margolis, W Gao, MH Voss, W Li, DJ Martini, C Norton, ... Science 359 (6377), 801-806, 2018 | 1000 | 2018 |
| The long tail of oncogenic drivers in prostate cancer J Armenia, SAM Wankowicz, D Liu, J Gao, R Kundra, E Reznik, ... Nature genetics 50 (5), 645-651, 2018 | 731 | 2018 |
| Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors D Miao, CA Margolis, NI Vokes, D Liu, A Taylor-Weiner, SM Wankowicz, ... Nature genetics 50 (9), 1271-1281, 2018 | 496 | 2018 |
| Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing SR Viswanathan, G Ha, AM Hoff, JA Wala, J Carrot-Zhang, CW Whelan, ... Cell 174 (2), 433-447. e19, 2018 | 320 | 2018 |
| Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma J Bellmunt, SA Mullane, L Werner, AP Fay, M Callea, JJ Leow, ME Taplin, ... Annals of oncology 26 (4), 812-817, 2015 | 311 | 2015 |
| DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma MY Teo, RM Bambury, EC Zabor, E Jordan, H Al-Ahmadie, ME Boyd, ... Clinical cancer research 23 (14), 3610-3618, 2017 | 243 | 2017 |
| Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer DN Rodrigues, P Rescigno, D Liu, W Yuan, S Carreira, MB Lambros, ... The Journal of clinical investigation 128 (10), 4441-4453, 2018 | 204 | 2018 |
| Neoadjuvant chemotherapy prior to radical cystectomy for muscle‐invasive bladder cancer with variant histology MW Vetterlein, SAM Wankowicz, T Seisen, R Lander, B Löppenberg, ... Cancer 123 (22), 4346-4355, 2017 | 163 | 2017 |
| Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations FW Huang, JM Mosquera, A Garofalo, C Oh, M Baco, A Amin-Mansour, ... Cancer discovery 7 (9), 973-983, 2017 | 120 | 2017 |
| Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer D Liu, P Abbosh, D Keliher, B Reardon, D Miao, K Mouw, A Weiner-Taylor, ... Nature communications 8 (1), 2193, 2017 | 116 | 2017 |
| Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles P Cejas, L Li, NK O'Neill, M Duarte, P Rao, M Bowden, CW Zhou, ... Nature medicine 22 (6), 685-691, 2016 | 115 | 2016 |
| The clinical activity of PD-1/PD-L1 inhibitors in metastatic non–clear cell renal cell carcinoma RR McKay, D Bossé, W Xie, SAM Wankowicz, A Flaifel, R Brandao, ... Cancer immunology research 6 (7), 758-765, 2018 | 113 | 2018 |
| Integrative molecular characterization of resistance to neoadjuvant chemoradiation in rectal cancer SC Kamran, JK Lennerz, CA Margolis, D Liu, B Reardon, SA Wankowicz, ... Clinical Cancer Research 25 (18), 5561-5571, 2019 | 75 | 2019 |
| Cryo-EM model validation recommendations based on outcomes of the 2019 EMDataResource challenge CL Lawson, A Kryshtafovych, PD Adams, PV Afonine, ML Baker, ... Nature methods 18 (2), 156-164, 2021 | 73 | 2021 |
| Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma G Sonpavde, GR Pond, TK Choueiri, S Mullane, G Niegisch, P Albers, ... European Urology 69 (4), 634-641, 2016 | 65 | 2016 |
| Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients A Orsola, L Werner, I De Torres, W Martin-Doyle, CX Raventos, F Lozano, ... British journal of cancer 112 (3), 468-474, 2015 | 63 | 2015 |
| HER2 as a target in invasive urothelial carcinoma J Bellmunt, L Werner, A Bamias, AP Fay, RS Park, M Riester, ... Cancer medicine 4 (6), 844-852, 2015 | 60 | 2015 |
| Genomic predictors of good outcome, recurrence, or progression in high-grade t1 non–muscle-invasive bladder cancer J Bellmunt, J Kim, B Reardon, J Perera-Bel, A Orsola, A Rodriguez-Vida, ... Cancer research 80 (20), 4476-4486, 2020 | 58 | 2020 |
| CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer JH Hwang, JH Seo, ML Beshiri, S Wankowicz, D Liu, A Cheung, J Li, ... Cell reports 29 (8), 2355-2370. e6, 2019 | 51 | 2019 |
